MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
12.23
+0.38
+3.21%
After Hours: 12.84 +0.61 +4.99% 18:53 02/06 EST
OPEN
12.09
PREV CLOSE
11.85
HIGH
12.53
LOW
11.86
VOLUME
420.20K
TURNOVER
--
52 WEEK HIGH
13.43
52 WEEK LOW
5.68
MARKET CAP
722.50M
P/E (TTM)
-3.3233
1D
5D
1M
3M
1Y
5Y
1D
TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead”
TipRanks · 3d ago
Cullinan Therapeutics Price Target Announced at $30.00/Share by Guggenheim
Dow Jones · 5d ago
Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga · 5d ago
Weekly Report: what happened at CGEM last week (0126-0130)?
Weekly Report · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Synergy CHC (SNYR), Cullinan Management (CGEM)
TipRanks · 5d ago
Cullinan Therapeutics initiated with a Buy at Guggenheim
TipRanks · 6d ago
Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers
Seeking Alpha · 01/29 04:03
Weekly Report: what happened at CGEM last week (0119-0123)?
Weekly Report · 01/26 09:55
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.